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Significant progress toward the control of malaria has been achieved, especially regarding Plasmodium falciparum infections.
However, the unique biology of Plasmodium vivax hampers current control strategies. The early appearance of P. vivax gameto-
cytes in the peripheral blood and the impossibility of culturing this parasite are major drawbacks. Using blood samples from 40
P. vivax-infected patients, we describe here a methodology to purify viable gametocytes and further infect anophelines. This
method opens new avenues to validate transmission-blocking strategies.
In a scenario of malaria elimination, strategies based on trans-mission control, rapid diagnosis, effective vaccines, and specific
drugs are vital. Early diagnosis and prompt treatment with effec-
tive drugs have led to a considerable decrease in the number of
cases of falciparum malaria worldwide (1). However, the control
and elimination of Plasmodium vivax still constitute a great chal-
lenge due to specific features of the organism, including gameto-
cytes on peripheral blood early during infection (2), occurrence of
a dormant stage in the liver (hypnozoite), and the emergence of
drug-resistant forms (3, 4). The development of transmission-
blocking molecules to reduce transmission is crucial for malaria
eradication. However, because of the lack of a robust continuous
in vitro culture system (5), studies on P. vivax gametocytes have
been hampered. Here, using blood samples from 40 P. vivax-in-
fected patients and membrane feeding assays, we describe a
unique methodology to purify and concentrate viable gameto-
cytes capable of infecting anophelines. This methodology opens
avenues for testing drugs or vaccines against the gametocytes, the
nonreplicating sexual stage responsible for parasite transmission
to mosquitoes (2).
Patients were recruited at the Fundação de Medicina Trop-
ical Dr. Heitor Vieira Dourado (FMT-HVD), a tertiary care
center for infectious diseases in Manaus, Amazonas State, Bra-
zil. This study was approved by a Brazilian ethics board (CAAE
0044.0.114.000-11). Up to 9 ml of peripheral blood was col-
lected from infected patients, with parasitemia ranging from
297.5 to 30,600 parasites/l and gametocytemia (mean stan-
dard deviation [SD]) of 13.3% 16.7%.White blood cells were
removed from the blood using a cellulose column (Sigma), as
previously described (6). Afterwards, to separate asexual and
sexual parasites from noninfected erythrocytes, we used a Per-
coll-45% (P45) or Percoll-60% (P60) gradient (7, 8) and/or
magnetic purification (MP) using MACS-Columns LD/LS
(Miltenyi Biotec) (9). Blood samples were maintained at 37°C
during all procedures to avoid gametocyte exflagellation. For
this purpose, we used a hot plate inside the tissue culture hood
and preheated solutions, and all centrifugations were per-
formed at 37°C. The percentage of gametocytes was deter-
mined by counting parasites on thin Giemsa smears before and
after the purification process. Correlations were analyzed using
the Spearman test. The normality of the data was evaluated
with the Kolmogorov-Smirnov test. Comparisons between
groups were analyzed using the Mann-Whitney U test (two
groups) or the Kruskal-Wallis test. Statistical analyses were
performed using GraphPad Prism version 6.
The P45 treatment led to the recovery of trophozoites, schi-
zonts, and gametocytes. A considerable percentage of parasites
at the gametocyte stage was obtained (mean  SD, 44.1% 
33.88%; Fig. 1A) and a considerable amount of trophozoites as
well (50.3% 34.17). Moreover, by performingMP after the P45
treatment, we were not able to improve the gametocyte purity
(54.3% 41.65%,P 0.70) or the parasitemia (47.7% 50.54%,
P  0.46) (Fig. 1A and B). In contrast, after P60 purification,
gametocytes were recovered, with low percentages of other para-
site stages (gametocytes, 81.6%  30.50%; Fig. 1A). Despite the
high degree of purification, noninfected erythrocytes were also
found in the P60 interphase that contained gametocytes (para-
sitemia, 18.9% 27.34%) (Fig. 1B). The P60 procedure rendered
significantly higher percentages of gametocytes than those with
the P45 procedure (81.6% versus 44.15%, P 0.0049).
Performing MP after the P60 procedure did not improve
the percentage of gametocytes recovered (79.9%  38.64%,
P 0.54) or the parasitemia level (34.7% 40.49%, P 0.65).
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Nevertheless, when the MP method was applied alone, we ob-
tained a gametocytemia of 62.13%  39.20% (Fig. 1A) and a
parasitemia of 53.8%  45.74% (Fig. 1B). This procedure al-
lowed us to enrich for parasites with large amounts of hemo-
zoin, resulting in only the mature asexual stage (30 h) and
gametocytes retained on the magnetic column (9). No associ-
ation between the yield of gametocytes after purification and
the initial gametocytemia of the patients was found (Fig. 1C).
Figure 1D shows a step-by-step schematic flow of all purifica-
tion procedures.
Considering that robust drug tests rely on parasite viability
and infectivity, we conducted the artificial membrane feeding
assays only after we established the procedures to purify and
increase the number of gametocytes. Those assays were per-
formed using an established colony of the Anopheles aquasalis
mosquito vector, as described elsewhere (10). Successful infec-
tions were determined by the presence of oocysts in the midgut
of the mosquitoes.
A. aquasalis, Anopheles albitarsis, and Anopheles darlingi are
the main vectors in South America and are associated with
malaria transmission (11). A. aquasalis has successfully been
used under laboratory conditions for P. vivax infections (10),
and an infection protocol with P. vivax on A. darlingi was re-
cently established (12). For these assays, purified gametocytes
were used to prepare blood dilutions at a hematocrit level of
36% using washed uninfected fresh O blood and AB serum at
a final volume of 1 ml. Next, 100 mosquitoes were fed on these
samples and reared accordingly (10). Prior to infection, the
viability of the gametocytes was tested by exflagellation assays.
Briefly, 10 l of purified gametocytes and autologous serum
were placed on a microscope slide for 10 min, and exflagella-
tion was visualized with the aid of a light microscope (Fig. 2A).
FIG1 P. vivax gametocyte purification. (A)Gametocytemia as gametocytes/total parasites (as a percentage) before and after the indicated purification processes.
P45, Percoll 45%; P60, Percoll 60%; MP, magnetic purification. The short horizontal lines represent the analysis between the same procedure before and after
purification. The long horizontal line represents the comparison of gametocytemia between P45 and P60 after purification. *, P  0.05; ***, P  0.001. (B)
Parasitemia (total parasites/total erythrocyte [as a percentage]) after indicated purification processes. The columns represent the means and the error bars
represent the SD. (C). Correlation between gametocytemia before and after purification. The dark solid line represents the linear regression and the dashed lines
represent the 95% confidence limit. (D) Step-by-step schematic and comparative representation of the three procedures.
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The capacity of P. vivax purified gametocytes to infect mosqui-
toes was evaluated in P45 purification and confirmed by the
visualization of oocysts in the midgut (Fig. 2B). As shown in
Fig. 2C, the infectivity rate of mosquitoes fed with dilutions
prepared with P45 purified gametocytes ranged from 25.0% to
73.1% (mean  SD, 54.0%  15.2%). The median number of
oocysts produced in mosquitoes fed with P. vivax P45 purified
gametocytes was 4.0 (interquartile range [IQR], 2.0 to 8.0
oocysts). Moreover, we found no correlation between the
number of gametocytes given to mosquitoes and the infection
rate (Fig. 2D) or the number of oocysts in infected mosquitoes
(Fig. 2E). These data, a representation of the results from 8
independent experiments (Fig. 2A to C), demonstrate that the
purified gametocytes were viable (exflagellation) and infective
(oocyst production in the midgut of the mosquitoes).
Based on the different gametocyte purification method out-
comes, the choice of procedure will depend on the goal to be
achieved. The P60method will be more appropriate for obtaining
gametocytes in the absence of asexual parasite stages. To achieve
high concentrations of parasites, the use of P45 orMPalonewill be
the best choice, because the combination of these methodologies
(P45 plus MP or P60 plus MP) did not improve the gameto-
cytemia or parasitemia levels. Collectively, these data validate a
methodology to purify viable and infective P. vivax gametocytes,
assisting in the discovery of new antimalarial drug leads and vac-
cine candidates.
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